Navigation Links
Organovo to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/19/2013

SAN DIEGO, Nov. 19, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) (" Organovo "), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has been invited to present at the 25th Annual Piper Jaffray Healthcare Conference, which will be held in New York December 3-4, 2013.

Organovo's Chairman and Chief Executive Officer, Keith Murphy, will be presenting on Wednesday, December 4, at 3:30pm ET  Mr. Murphy will also be participating in a panel discussion on 3D Printing on Tuesday, December 3, at 2:00pm ET.

The goal of Piper Jaffray's 25th Annual Healthcare Conference is to bring together key industry executives, investors and Piper professionals to provide multiple perspectives, investigate critical trends and identify the leaders in the markets that are driving our economy.  The conference will be held at The New York Palace – New York.

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our report on Form 10-Q filed November 8, 2013, the prospectus supplement filed with the SEC on August 2, 2013 and the transition report on Form 10-KT filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

 


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
2. Population Council to present more than 40 studies at International Conference on Family Planning
3. Experts from NYU Langone present new research at American College of Rheumatology 2013 Annual Meeting
4. Common bias known as the endowment effect not present in hunter-gatherer societies
5. Pest control presentations at Entomology 2013
6. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
7. Array BioPharma to Present at the NewsMakers in the Biotech Industry Conference
8. New research on potential avocado health benefits presented at International Congress of Nutrition
9. Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
10. Yin-yang effect of sodium and chloride presents salt conundrum
11. Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , ... AFM Luncheon for all SPIE attendees and Park customers on Feb. ... block from the San Jose Convention Center. The luncheon will feature a talk ...
(Date:2/22/2017)... Fort Washington, PA (PRWEB) , ... ... ... The Omnia-Prova Education Collaborative (TOPEC), the leading medical education provider of ... Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME). ...
(Date:2/22/2017)... ... , ... LabRoots , the leading provider of educational and interactive virtual ... announce the launch of a new scholarship for young scientists seeking a degree in ... is open to all high school seniors, 17 years or older; as well as ...
(Date:2/22/2017)... 2017 Aethlon Medical, Inc. (Nasdaq: ... that validated the ability of the Aethlon Hemopurifier® to ... mortality in immune-suppressed sepsis patients and also contribute to ... objective of the study was to validate the ... (EBV) and Herpes Simplex virus 1 (HSV1) by the ...
Breaking Biology Technology: